FASLG and neoplasm: Urinary bladder carcinoma acquires the functional FasL during tumour progression that may induce apoptosis of anti-tumour T lymphocytes and is suggested to be a crucial factor for selecting patients requiring more aggressive treatment and may be a crucial test to integrate into the surveillance protocol for patients with superficial bladder cancer, especially if refractory to BCG, augmenting the decision to early aggressive treatment.